Regarding APOC3, increasing evidence suggests that elevated plasma levels of ApoC3 are positively correlated with increased circulating triglyceride concentration and cardiovascular disease (CVD) incidence.[33] Human knockout studies of ApoC3 have shown that ApoC3 deficiency lowers plasma triglyceride and cholesterol levels and increases HDL-C levels.[34] From a microcirculatory perspective, the inhibition of APOC3 is a protective factor for SNHL. This evidence concerns the gene APOC3 and sensorineural hearing loss disorder.